Authors: Bennett, CL Hynes, D Godwin, J Stinson, TJ Golub, RM Appelbaum, FR

Citation: Cl. Bennett et al., Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): Estimates from a Southwest Oncology Group clinical trial, CANCER INV, 19(6), 2001, pp. 603-610

Authors: Bennett, CL Weinberg, PD Golub, RM Bussel, JB

Citation: Cl. Bennett et al., The potential for treatment of idiopathic thrombocytopenic purpura with anti-D to prevent splenectomy: A predictive cost analysis, SEM HEMATOL, 37(1), 2000, pp. 26-30

Authors: Bennett, CL Stinson, TJ Tallman, MS Stadtmauer, EA Marsh, RW Friedenberg, W Lazarus, HM Kaminer, L Golub, RM Rowe, JM

Citation: Cl. Bennett et al., Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia, ANN ONCOL, 10(2), 1999, pp. 177-182

Authors: Bennett, CL Weinberg, PO Golub, RM

Citation: Cl. Bennett et al., Cost-effectiveness model of a phase II clinical trial of a new pharmaceutical for essential thrombocythemia: Is it helpful to policy makers?, SEM HEMATOL, 36(1), 1999, pp. 26-29